Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Renal-Cell Carcinoma
Renal-Cell Carcinoma
,
Conference Highlights ASCO
,
Oncology
Adjuvant Pembrolizumab Therapy Significantly Extends Disease-Free Survival in Patients with Clear-Cell Renal-Cell Carcinoma
Phoebe Starr
Phoebe Starr
Read More
Renal-Cell Carcinoma
,
Oncology
Avelumab plus Axitinib New First-Line Standard of Care in Advanced Renal-Cell Carcinoma
Chase Doyle
Chase Doyle
Read More
Renal-Cell Carcinoma
,
Oncology
First-Line Treatments for Metastatic Renal-Cell Carcinoma Are Evolving
Read More
Renal-Cell Carcinoma
,
Oncology
Tivozanib Outperforms Sorafenib as First-Line Treatment in Advanced Renal-Cell Carcinoma
Read More
Renal-Cell Carcinoma
,
Oncology
Axitinib Dose Titration Up Enhances Outcomes in Metastatic Renal-Cell Carcinoma
Wayne Kuznar
Read More
Renal-Cell Carcinoma
,
Oncology
Quality of Life Drives Patient Preference for Metastatic RCC Drug
Wayne Kuznar
Read More
Results 1 - 6 of 6